Pharmaceutical Formulations Manufacturing Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Pharmaceutical formulations manufacturing plant sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹15 crore - ₹250 crore CapEx this DPR captures:

• WHO-GMP and Schedule M revised standards compliance
• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016
• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>India's pharmaceutical manufacturing landscape is distinguished by its remarkable scale and geographic distribution. The sector comprises approximately 10,500 manufacturing units spread across roughly 3,000 drug companies, organized into 118 active pharmaceutical clusters distributed across 19 states and union territories. Geographically, the Western Region dominates with 55% of clusters (65 clusters), followed by the Southern Region at 22% (26 clusters), the Northern and Central Region at 19% (23 clusters), and the Eastern Region at just 3%, indicating significant room for regional expansion in underserved eastern states.</p><p>The industry's global standing is underpinned by its USFDA-compliant infrastructure: India hosts approximately 670 USFDA-approved manufacturing facilities, the highest number outside the United States.

In the active pharmaceutical ingredient (API) segment, over 500 API producers in India contribute approximately 8% to global API output. The country's trade performance reflects strong competitiveness, with pharmaceutical exports totaling USD 30.47 billion in FY2024-25, up 9.4% year-over-year, against imports of USD 8.9 billion, resulting in a trade surplus of USD 21.5 billion. Within exports, drug formulations and biologics accounted for USD 22.92 billion, representing approximately 75% of total pharmaceutical export share.

Domestic consumption of formulations was valued between USD 23.5 billion and USD 41 billion, indicating a robust internal market alongside export demand.</p><p>Manufacturing economics at the production level reflect favorable unit economics. Production costs for tablets and capsules range from INR 0.80 to INR 3.20 per blister strip containing 10 units, while liquid syrups (60ml to 100ml) cost INR 18 to INR 35 per bottle and injectables range from INR 50 to INR 150+ per vial. Minimum batch costs for tablets or capsules of 30,000 to 50,000 units fall in the range of INR 40,000 to INR 95,000 per batch, demonstrating the cost-competitive nature of Indian pharmaceutical manufacturing.</p>

Project-specific demand drivers

• Generic drug exports
• PLI Bulk Drug & Medical Devices
• Domestic chronic disease demand
• CDMO opportunity

<p>The pharmaceutical manufacturing sector in India is undergoing a significant technological transformation, transitioning from traditional batch processing toward Continuous Manufacturing (CM) and Smart Factory ecosystems. These next-generation approaches leverage artificial intelligence, digital twins, and modular infrastructure to reduce operational costs, enhance quality control, and improve manufacturing flexibility. Continuous Manufacturing, in particular, represents a departure from the historically dominant batch processing paradigm, offering streamlined production flows and real-time process monitoring capabilities that align with global regulatory expectations.</p><p>The smart manufacturing segment associated with pharmaceutical production is experiencing rapid growth.

The Smart Manufacturing Market is estimated at USD 14.72 billion in 2026 and is projected to reach USD 32.49 billion by 2034 at a compound annual growth rate of 10.40%, according to Fortune Business Insights. Complementing this, the Pharmacy Automation Market is valued at USD 7.81 billion in 2026 and is expected to scale to USD 11.79 billion by 2031 at a CAGR of 8.60%, as reported by Mordor Intelligence. These technology segments are driving efficiency gains across manufacturing, warehousing, and quality assurance operations throughout the Indian pharmaceutical industry.</p><p>Energy efficiency and sustainability have also become critical considerations for modern pharmaceutical facilities.

The median Energy Use Intensity (EUI) for pharmaceutical facilities stands at 4,391 kWh per square meter (1,391 kBtu per square foot), with top-quartile facilities achieving energy performance levels that qualify for U.S. EPA ENERGY STAR certification. For new plant investments, achieving competitive EUI benchmarks is increasingly important for both operational cost management and global compliance positioning.</p>

The recommended means of finance for this project, falling within the ₹15 crore to ₹250 crore CapEx band, follows a tiered debt-equity structure calibrated to project scale and lender appetite. For projects in the ₹15 crore to ₹75 crore bracket, a 70:30 debt-to-equity ratio is recommended, with equity contributed by the promoter and qualifying venture or growth capital. For projects exceeding ₹75 crore, leverage may extend to 75:25, with a combination of term loan and project finance structures.

Primary lending institutions for pharmaceutical formulations projects include State Bank of India and its subsidiary SBI Capital Markets, which maintain dedicated pharma manufacturing desk teams and have historically financed Baddi, Sikkim, and Hyderabad cluster expansions. HDFC Bank and ICICI Bank offer structured project finance for Schedule M-compliant facilities with interest rates starting from 8.75 percent for well-rated promoters. IDBI Bank and Axis Bank have active manufacturing lending mandates and are responsive to projects with long-term supply agreements. SIDBI provides rupee term loan financing for MSME-classified projects in the sub-₹50 crore CapEx bracket, with interest concessions for units in notified thrust sectors and backward areas. For projects qualifying under the PLI Scheme for Bulk Drugs and Medical Devices, capital incentive grants of up to 20 percent of eligible CapEx are available, reducing effective equity requirement materially. Working capital assessment for formulations manufacturers typically follows a 90-120 day cycle, comprising 45-60 days of inventory (API and packaging materials), 30-45 days of debtors through stockist channel, and 15-25 days of creditors. A working capital limits of ₹8-12 crore is typical for a ₹50 crore formulations plant operating at 60-70 percent capacity utilisation. State-level incentives including SGST reimbursement, electricity duty exemption, and stamp duty concessions in states such as Gujarat, Himachal Pradesh, Uttarakhand, and Telangana materially improve project IRR by 150-200 basis points over a 10-year concession period.

<p>Despite its strong fundamentals, the Indian pharmaceutical manufacturing sector faces several structural and operational risks that warrant careful consideration in investment planning. Geographic supply concentration poses a critical vulnerability: as of 2026, 44% of drugs currently in shortage contain at least one Key Starting Material (KSM) produced solely in a single country, creating supply chain fragility that could disrupt production continuity and regulatory compliance for manufacturers dependent on single-source imported inputs.</p><p>Regulatory risk remains an ever-present consideration. While India has made significant strides with the Revised Schedule M notified on December 28, 2023, and integration of WHO-GMP, EU-GMP, and USFDA standards, maintaining compliance across multiple regulatory jurisdictions is resource-intensive.

USFDA observations and import alerts can significantly impact export-oriented manufacturers, and the regulatory landscape continues to evolve with periodic amendments to the Drugs and Cosmetics Rules and new quality system expectations.</p><p>Labor and skills shortages represent a growing operational risk, particularly as manufacturing becomes more technology-intensive. The shift toward continuous manufacturing, smart factory operations, and advanced quality systems demands specialized skills that are in limited supply. While the U.S.

Bureau of Labor Statistics projects pharmaceutical and medicine manufacturing employment to grow to 369,500 jobs by 2034 from 350,500 in 2024, India faces its own talent pipeline challenges in advanced pharmaceutical manufacturing technologies. The sector's median energy use intensity of 4,391 kWh per square meter also highlights the operational cost exposure associated with energy-intensive manufacturing processes, particularly in the context of rising energy costs and tightening sustainability norms.</p><p>Market concentration risk exists alongside the broader growth outlook. Despite favorable long-range projections, actual market realization depends on factors including regulatory approval timelines, global pricing pressures, patent litigation, and currency fluctuations affecting export competitiveness.

The CDMO alternative also represents a competitive risk for companies considering fully owned plant investments, as outsourcing to established CDMOs like Lonza, Catalent, and Thermo Fisher Scientific may offer lower capital requirements and faster time-to-market for certain product categories. Additionally, while the PLI Scheme has driven substantial investment, its eventual conclusion in FY2028-29 could create a post-incentive gap that affects the investment calculus for projects planned around incentive-supported economics.</p>